ECSP024346A - Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico - Google Patents

Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico

Info

Publication number
ECSP024346A
ECSP024346A EC2002004346A ECSP024346A ECSP024346A EC SP024346 A ECSP024346 A EC SP024346A EC 2002004346 A EC2002004346 A EC 2002004346A EC SP024346 A ECSP024346 A EC SP024346A EC SP024346 A ECSP024346 A EC SP024346A
Authority
EC
Ecuador
Prior art keywords
act
glon
peptides
methods
pharmacological use
Prior art date
Application number
EC2002004346A
Other languages
English (en)
Inventor
Kevin Clairmont
Clark Pan
James Whelan
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of ECSP024346A publication Critical patent/ECSP024346A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención provee polipéptidos que actúan como agonostas del receptor del GLP-1 y como antagonistass del receptor del glucagón. Dichos polipéptidos son útiles para el tratamiento de individuos con diabetes tipo 2 u otros trastornos metabólicos.
EC2002004346A 2001-10-05 2002-11-20 Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico ECSP024346A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32773001P 2001-10-05 2001-10-05

Publications (1)

Publication Number Publication Date
ECSP024346A true ECSP024346A (es) 2003-05-26

Family

ID=23277790

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2002004346A ECSP024346A (es) 2001-10-05 2002-11-20 Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
EC2004005094A ECSP045094A (es) 2001-10-05 2004-05-05 Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico

Family Applications After (1)

Application Number Title Priority Date Filing Date
EC2004005094A ECSP045094A (es) 2001-10-05 2004-05-05 Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico

Country Status (27)

Country Link
US (6) US7399745B2 (es)
EP (1) EP1436330A4 (es)
JP (1) JP2005508639A (es)
KR (1) KR20050034580A (es)
CN (1) CN1326876C (es)
AR (1) AR036711A1 (es)
BR (1) BR0213132A (es)
CA (1) CA2462462A1 (es)
CO (1) CO5570710A2 (es)
DO (1) DOP2002000475A (es)
EC (2) ECSP024346A (es)
HN (1) HN2002000282A (es)
HR (1) HRP20040327A2 (es)
HU (1) HUP0401797A2 (es)
IL (1) IL160706A0 (es)
MA (1) MA26228A1 (es)
MX (1) MXPA04002140A (es)
MY (1) MY138267A (es)
NO (1) NO20041792L (es)
NZ (1) NZ532685A (es)
PE (1) PE20030850A1 (es)
PL (1) PL368760A1 (es)
RU (1) RU2334761C2 (es)
SG (2) SG158736A1 (es)
UY (1) UY27469A1 (es)
WO (1) WO2003040309A2 (es)
ZA (1) ZA200403322B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2497794A1 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
US7557183B2 (en) 2003-03-19 2009-07-07 Eli Lilly And Company Polyethylene glycol linked GLP-1 compounds
US20050124550A1 (en) * 2003-06-18 2005-06-09 Peri Krishna G. Compounds that modulate the glucagon response and uses thereof
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ 新規なｇｌｐ−１化合物
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
CA2913805A1 (en) * 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
JO2945B1 (en) 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
CN101578102B (zh) * 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2008098693A2 (en) * 2007-02-16 2008-08-21 Bayer Healthcare Ag Convergent synthesis of glp-1
CA2707861A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Glucagon antagonists
WO2009058734A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
KR101277560B1 (ko) * 2007-12-11 2013-06-25 카딜라 핼쓰캐어 리미티드 글루카곤 안타고니스트 활성 및 ｇｌｐ-1 아고니스트 활성의 펩티드 유사체
US20110065633A1 (en) * 2008-01-30 2011-03-17 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
AR070844A1 (es) * 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
TWI541023B (zh) * 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
CA2728284C (en) * 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
ES2558842T3 (es) * 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
RU2012153753A (ru) 2010-05-13 2014-06-20 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
ES2661228T3 (es) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
RU2623049C2 (ru) 2011-03-04 2017-06-21 Бектон, Дикинсон энд Кампани Устройство для взятия крови, содержащее ингибитор лизофосфолипазы
CN103857408B (zh) 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
ES2602486T3 (es) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento
MY186251A (en) 2014-01-20 2021-06-30 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
WO2015168135A1 (en) * 2014-04-28 2015-11-05 The Trustees Of The University Of Pennsylvania Novel thioamide-modified peptides and uses thereof
WO2015183984A2 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) * 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
CN106535920B (zh) 2014-07-21 2020-10-30 代表亚利桑那大学的亚利桑那校董会 Ang-(1-7)衍生物寡肽及其使用和生产方法
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
AU2017332408B2 (en) 2016-09-23 2022-02-10 Hanmi Pharm. Co., Ltd. Insulin analogs with reduced affinity to insulin receptor and use thereof
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
JP2021513564A (ja) 2018-02-13 2021-05-27 リガンド・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体拮抗薬
EP3891176B1 (en) 2018-12-04 2024-06-05 Holst, Birgitte Dual agonist glp-1 and neurotensin fusion peptide
US12591761B2 (en) 2018-12-05 2026-03-31 Shape Security, Inc. Execution of trained neural networks using a database system
US11934931B2 (en) * 2018-12-17 2024-03-19 Shape Security, Inc. Decision tree training using a database system
WO2020254479A1 (en) * 2019-06-18 2020-12-24 Fresenius Kabi Ipsum S.R.L. Process for the manufacture of glucagon
US12406209B1 (en) 2019-06-28 2025-09-02 Shape Security, Inc. Decision tree training using a database system
CN113728013B (zh) 2020-01-11 2022-06-14 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
KR20260010739A (ko) 2023-05-11 2026-01-21 유니버시티 하스피탈즈 클리블랜드 메디컬 센터 항불안 치료

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2113879T3 (es) * 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
DE69209052T2 (de) * 1991-01-17 1996-11-14 Zymogenetics Inc Verfahren zum nachweis von glucagon-antagonisten
US5846747A (en) * 1992-03-25 1998-12-08 Novo Nordisk A/S Method for detecting glucagon-like peptide-1 antagonists and agonists
US5480867A (en) * 1993-12-29 1996-01-02 The Rockefeller University Glucagon analogs with serine replacements
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
US5782802A (en) * 1996-03-22 1998-07-21 Vitajet Corporation Multiple use needle-less hypodermic injection device for individual users
US6232310B1 (en) * 1999-03-12 2001-05-15 Novo Nordisk A/S Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists

Also Published As

Publication number Publication date
SG158736A1 (en) 2010-02-26
US20060003934A1 (en) 2006-01-05
US7494978B2 (en) 2009-02-24
US7488714B2 (en) 2009-02-10
ZA200403322B (en) 2005-05-03
MY138267A (en) 2009-05-29
MXPA04002140A (es) 2005-03-07
US20060003419A1 (en) 2006-01-05
IL160706A0 (en) 2004-08-31
WO2003040309A2 (en) 2003-05-15
US7399745B2 (en) 2008-07-15
JP2005508639A (ja) 2005-04-07
HN2002000282A (es) 2002-12-12
RU2004114243A (ru) 2005-05-10
NO20041792L (no) 2004-07-02
SG149693A1 (en) 2009-02-27
UY27469A1 (es) 2003-04-30
HK1073117A1 (zh) 2005-09-23
CA2462462A1 (en) 2003-05-15
DOP2002000475A (es) 2003-06-30
KR20050034580A (ko) 2005-04-14
EP1436330A4 (en) 2006-01-18
US7488716B2 (en) 2009-02-10
CN1564828A (zh) 2005-01-12
MA26228A1 (fr) 2004-07-01
BR0213132A (pt) 2004-10-19
US20050288248A1 (en) 2005-12-29
NZ532685A (en) 2006-02-24
US20060003418A1 (en) 2006-01-05
EP1436330A2 (en) 2004-07-14
AR036711A1 (es) 2004-09-29
ECSP045094A (es) 2004-06-28
US20060003417A1 (en) 2006-01-05
PE20030850A1 (es) 2003-10-31
CN1326876C (zh) 2007-07-18
PL368760A1 (en) 2005-04-04
HRP20040327A2 (en) 2007-11-30
WO2003040309A3 (en) 2003-12-18
US20050153890A1 (en) 2005-07-14
RU2334761C2 (ru) 2008-09-27
CO5570710A2 (es) 2005-10-31
HUP0401797A2 (en) 2006-08-28
US7488715B2 (en) 2009-02-10

Similar Documents

Publication Publication Date Title
ECSP045094A (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico
ES2146552B1 (es) Peptidos inhibidores de tgf/31
EP3878868A4 (en) HUMAN ANTIBODY WITH HIGH AFFINITY TO AND USE OF HUMAN IL-4 RECEPTOR ALPHA
AR064032A1 (es) Usos terapeuticos de polipeptidos heterologos il-17a/f
ECSP045382A (es) Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa
CO6362020A2 (es) Mutantes fgf21 y uso de los mismos
CR20110556A (es) Proteinas de fusion rage y metodos de empleo
GT200300142A (es) Agonistas del receptor (vpac2) del peptido activante de la adenilato ciclasa hipofisaria (pacap) y sus metodos de uso farmacologicos
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
AR103242A1 (es) Compuestos co-agonistas de gip y glp-1
CY1117476T1 (el) Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων
NO20001599D0 (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
NO20060259L (no) Melanocortinreseptor 4(MC4) agonist og anvendelser derav
PE20200150A1 (es) Uso de antagonistas de klk5 para el tratamiento de una enfermedad
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
PE20221271A1 (es) Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas
ES2125567T3 (es) Uso de un antagonista de serotonina en combinacion con un antagonista del receptor de taquiquinina para la fabricacion de un medicamento para la prevencion o el tratamiento de la migraña.
AR030554A1 (es) Moleculas similares a receptores il-17 y usos de las mismas
ES2171196T3 (es) Uso de antagonistas del receptor cck-b para el tratamiento de trastornos del sueño.
DK1899334T3 (da) Naphthyridinforbindelser
WO2003018798A3 (en) G-protein coupled receptor and dna sequences thereof
EP1695968A4 (en) AGONISTS OF GLUCAGON LIKE PEPTIDE-1 RECEPTOR, THEIR PREPARATION AND THEIR USE
DK1363944T3 (da) Höjaffinitetsantagonister for ELR-CXC-kemokiner